Plausible Improvements for Selective Targeting of Dopamine Receptors in Therapy of Parkinson’s Disease

Pratibha      Mehta Luthra; J.B.      Senthil Kumar

doi:10.2174/138955712803832645

Abstract

Parkinson’s disease (PD) is a neurodegenerative condition characterized by progressive and profound loss of dopaminergic neurons in the substantia nigra pars compacta leading to the formation of eosinophillic, intracytoplamic, proteinacious inclusions termed as lewy bodies. L-dopa remains as a gold standard for the treatment of PD, and is often combined with carbidopa to reduce the dose-limiting side effects. Long-term levodopa treatment is associated with the development of motor fluctuations and peak dose dyskinesias. Dopamine Replacement Therapy (DRT) with dopamine agonists (DAs) (ropinirole and pramipexole) is used to manage complications of L-dopa treatment, however, has been associated with numerous pharmacovigilence reports. The present review attempts to narrate the multiple receptor interaction of DAs followed by the assessment of their side effects during the treatment of PD and possible remedial strategy for selective targeting of dopamine receptors to overcome these affects in therapy of Parkinson's disease.

Keywords: Apomorphine, Bromocriptine, Dopamine Replacement Therapy, Dopamine receptor, Ergolines, Non-ergolines, dyskinesia, L-dopa treatment, serotonin, anti-parkinsonian